Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Hortense De Saint Basile"'
Autor:
Hortense De Saint Basile, Reza Elaidi, Zineb Maaradji, Hélène Blons, Rym BenDhiab, Laure Gibault, Elizabeth Fabre
Publikováno v:
Exploration of Targeted Anti-tumor Therapy, Vol 5, Iss 6, Pp 1435-1449 (2024)
Aim: Immune checkpoint inhibitors improved the survival of advanced non-small cell lung cancer. However, only 20% of patients respond to these treatments and the search for predictive biomarkers of response is still topical. The objective of this wor
Externí odkaz:
https://doaj.org/article/4774cfb85ae849a496c1a5d5a13816b1
Autor:
Hang Phuong Pham, Diane Damotte, Stéphanie Corgnac, Ludger Johannes, Eric Tartour, Léa Paolini, Fathia Mami-Chouaib, Karen Leroy, Pascaline Boudou-Rouquette, Helene Blons, Francois Goldwasser, Pierre Laurent-Puig, Isabelle Cremer, Milena Hasan, Thi Tran, Nadege Gruel, Laure Gibault, Elizabeth Fabre, Marie Wislez, Patrice Ravel, Valentin Quiniou, Jennifer Arrondeau, Aziza Caidi, Jean-Philippe Villemin, Jonathan Ulmer, Louis-Victorien Vieillard, Joséphine Pineau, Alain Gey, Pierre Barennes, Valentina Libri, Sebastien Mella, Sixtine De Percin, Hortense De Saint Basile
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 12 (2024)
Background A high density of resident memory T cells (TRM) in tumors correlates with improved clinical outcomes in immunotherapy-treated patients. In most clinical studies, TRM are defined by the CD103 marker. However, it is clearly established that
Externí odkaz:
https://doaj.org/article/e5b6260f3caa4e0bb90751e2a17c334d
Autor:
Mihaela Aldea, Arianna Marinello, Michael Duruisseaux, Wael Zrafi, Nicole Conci, Giacomo Massa, Giulio Metro, Isabelle Monnet, Patricia Gomez Iranzo, Fabrizio Tabbo, Emilio Bria, Florian Guisier, Damien Vasseur, Colin R. Lindsay, Santiago Ponce-Aix, Sophie Cousin, Fabrizio Citarella, Vincent Fallet, Jose Nicolas Minatta, Anna Eisert, Hortense de Saint Basile, Clarisse Audigier-Valette, Laura Mezquita, Antonio Calles, Giannis Mountzios, Marco Tagliamento, Jordi Remon Masip, Judith Raimbourg, Safae Terrisse, Alessandro Russo, Diego Cortinovis, Philippe Rochigneux, David James Pinato, Alessio Cortellini, Camille Leonce, Anas Gazzah, Maria-Rosa Ghigna, Roberto Ferrara, Filippo Gustavo Dall’Olio, Francesco Passiglia, Vienna Ludovini, Fabrice Barlesi, Enriqueta Felip, David Planchard, Benjamin Besse
Publikováno v:
Scientia
Chemotherapy; Non–small cell lung cancer; RET inhibitors Quimioteràpia; Càncer de pulmó de cèl·lules no petites; Inhibidors de RET Quimioterapia; Cáncer de pulmón de células no pequeñas; Inhibidores de RET Introduction Nearly 1% to 2% of N
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57f7bd4756ed222514ab170ab21d1c3d
https://doi.org/10.1016/j.jtho.2022.12.018
https://doi.org/10.1016/j.jtho.2022.12.018
Autor:
Ivan Pourmir, Reza Elaidi, Zineb Maaradji, Hortense de Saint Basile, Monivann Ung, Benoit Gazeau, Laure Fournier, Bastien Rance, Laure Gibault, Mohammed Ismaili, Elizabeth Fabre
AimsAnti-PD-1/PD-L1 can face the issue of tumor resistance in advanced non-small cell lung cancer (aNSCLC), mostly as primary resistance to the treatment. Still, disease progression (PD) also occurs after prior durable clinical benefit (DCB). Compari
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::00b83a990a93297887f05a11a9da50fd
https://doi.org/10.1101/2023.03.09.23287023
https://doi.org/10.1101/2023.03.09.23287023
Publikováno v:
Cancers. 15:1646
The development of immune checkpoint inhibitors (ICIs) constitutes a major therapeutic advance in the treatment of a number of malignancies [...]
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::59b448772200aab357983d3b7fcbb314
https://doi.org/10.3390/cancers15061646
https://doi.org/10.3390/cancers15061646
Publikováno v:
Cancer Drug Resistance.
Immune checkpoint inhibitors represent a major therapeutic advance in non-small-cell lung cancer with several approved anti-programmed death-1 and anti-programmed death-L1 immunotherapies. A majority of patients however, will not respond to immune ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63c1e2ea77b20d058c98cb56b31467e2
https://doi.org/10.20517/cdr.2020.14
https://doi.org/10.20517/cdr.2020.14